(FM) Hematología
Departamento académico
Mayo Clinic
Rochester, Estados UnidosPublikationen in Zusammenarbeit mit Forschern von Mayo Clinic (28)
2024
-
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387
-
Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma
Blood Advances
-
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216
-
Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma
Future Oncology, Vol. 20, Núm. 18, pp. 1221-1235
-
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma
Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152
2023
-
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)
Leukemia
-
Disease Monitoring In Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia
-
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
New England Journal of Medicine, Vol. 388, Núm. 11, pp. 1002-1014
-
Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel
Blood cancer discovery, Vol. 4, Núm. 5, pp. 365-373
2022
-
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma
Transplantation and Cellular Therapy, Vol. 28, Núm. 6, pp. 284-293
-
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
Blood, Vol. 139, Núm. 4, pp. 492-501
2021
-
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
Leukemia, Vol. 35, Núm. 1, pp. 18-30
-
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
Blood Cancer Journal, Vol. 11, Núm. 6
-
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report
Blood Cancer Journal, Vol. 11, Núm. 2
-
Minimal residual disease in Myeloma: Application for clinical care and new drug registration
Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212
-
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
Leukemia, Vol. 35, Núm. 12, pp. 3542-3550
-
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
Blood Cancer Journal, Vol. 11, Núm. 12
-
The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma
Transplantation and Cellular Therapy, Vol. 27, Núm. 10, pp. 807-816
2020
-
Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis
The Lancet Haematology, Vol. 7, Núm. 10, pp. e746-e755
-
The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis
Journal of Thrombosis and Haemostasis, Vol. 18, Núm. 8, pp. 1940-1951